Regeneron Pharmaceuticals, Inc. Q3 2025 Earnings Recap

Regeneron Pharmaceuticals reported solid third quarter results for 2025, with robust sales growth driven by Dupixent and Libtayo, complemented by EYLEA HD achieving record revenue despite ongoing affordability challenges.

Key Takeaways

• Dupixent generated $4.9 billion in global net sales, a 26% increase year-over-year, with dominance in multiple indications and growing patient base.
• Libtayo sales reached $365 million, up 24% year-over-year, bolstered by a recent FDA approval for use in high-risk adjuvant cutaneous squamous cell carcinoma.
• EYLEA HD sales hit an all-time high of $431 million in the U.S., driven by increased physician demand, though impacted by pricing pressures and market affordability issues.
• Ongoing regulatory challenges with prefilled syringe approvals for EYLEA HD could affect future growth potential; alternate filling plans set for submission by January 2026.
• Significant R&D progress announced with positive Phase III results across diverse therapeutic areas, enhancing pipeline momentum ahead of upcoming pivotal studies.